Given that estradiol is the main risk factor for endometrial cancer, data are consistent with the notion that downstream activation of the IGF1-mediated pathway by mutation could play a major role in the progression to ER-independent tumors (38). The gene discussed is IGF1; the disease is endometrial cancer.